Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Cedars-Sinai Medical Center, Los Angeles, California Georgetown University, Washington D.C., District of Columbia University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan